S&P 500   3,371.16 (-0.07%)
DOW   27,885.54 (-0.04%)
QQQ   271.93 (-0.20%)
AAPL   455.35 (-1.02%)
MSFT   208.40 (-0.14%)
FB   260.47 (-0.32%)
GOOGL   1,507.82 (-0.58%)
AMZN   3,137.10 (-0.76%)
NVDA   464.08 (+1.39%)
CGC   17.12 (-1.15%)
BABA   253.52 (-0.08%)
TSLA   1,642.92 (+1.35%)
GE   6.61 (+0.15%)
MU   45.79 (-0.76%)
AMD   82.72 (+1.08%)
T   29.88 (-0.10%)
F   7.04 (+0.14%)
GILD   68.52 (+0.50%)
NFLX   483.77 (+0.51%)
DIS   130.45 (-0.39%)
BAC   26.22 (-0.49%)
BA   173.99 (-0.42%)
S&P 500   3,371.16 (-0.07%)
DOW   27,885.54 (-0.04%)
QQQ   271.93 (-0.20%)
AAPL   455.35 (-1.02%)
MSFT   208.40 (-0.14%)
FB   260.47 (-0.32%)
GOOGL   1,507.82 (-0.58%)
AMZN   3,137.10 (-0.76%)
NVDA   464.08 (+1.39%)
CGC   17.12 (-1.15%)
BABA   253.52 (-0.08%)
TSLA   1,642.92 (+1.35%)
GE   6.61 (+0.15%)
MU   45.79 (-0.76%)
AMD   82.72 (+1.08%)
T   29.88 (-0.10%)
F   7.04 (+0.14%)
GILD   68.52 (+0.50%)
NFLX   483.77 (+0.51%)
DIS   130.45 (-0.39%)
BAC   26.22 (-0.49%)
BA   173.99 (-0.42%)
S&P 500   3,371.16 (-0.07%)
DOW   27,885.54 (-0.04%)
QQQ   271.93 (-0.20%)
AAPL   455.35 (-1.02%)
MSFT   208.40 (-0.14%)
FB   260.47 (-0.32%)
GOOGL   1,507.82 (-0.58%)
AMZN   3,137.10 (-0.76%)
NVDA   464.08 (+1.39%)
CGC   17.12 (-1.15%)
BABA   253.52 (-0.08%)
TSLA   1,642.92 (+1.35%)
GE   6.61 (+0.15%)
MU   45.79 (-0.76%)
AMD   82.72 (+1.08%)
T   29.88 (-0.10%)
F   7.04 (+0.14%)
GILD   68.52 (+0.50%)
NFLX   483.77 (+0.51%)
DIS   130.45 (-0.39%)
BAC   26.22 (-0.49%)
BA   173.99 (-0.42%)
S&P 500   3,371.16 (-0.07%)
DOW   27,885.54 (-0.04%)
QQQ   271.93 (-0.20%)
AAPL   455.35 (-1.02%)
MSFT   208.40 (-0.14%)
FB   260.47 (-0.32%)
GOOGL   1,507.82 (-0.58%)
AMZN   3,137.10 (-0.76%)
NVDA   464.08 (+1.39%)
CGC   17.12 (-1.15%)
BABA   253.52 (-0.08%)
TSLA   1,642.92 (+1.35%)
GE   6.61 (+0.15%)
MU   45.79 (-0.76%)
AMD   82.72 (+1.08%)
T   29.88 (-0.10%)
F   7.04 (+0.14%)
GILD   68.52 (+0.50%)
NFLX   483.77 (+0.51%)
DIS   130.45 (-0.39%)
BAC   26.22 (-0.49%)
BA   173.99 (-0.42%)
Log in

NASDAQ:AVCOAvalon Globocare Stock Price, Forecast & News

$1.76
+0.05 (+2.92 %)
(As of 08/14/2020 09:51 AM ET)
Add
Compare
Today's Range
$1.66
Now: $1.76
$1.85
50-Day Range
$1.57
MA: $1.70
$1.88
52-Week Range
$0.50
Now: $1.76
$2.65
Volume2.11 million shs
Average Volume257,085 shs
Market Capitalization$140.92 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65
Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership with Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy; a research and licensing agreement with Massachusetts Institute of Technology to develop technology for cellular therapy; and strategic partnership with GE Healthcare to enhance standardized automation and bio-production for cellular medicines. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Management consulting services
Sub-IndustryN/A
Current SymbolNASDAQ:AVCO
CUSIPN/A
Phone732-780-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.55 million
Book Value$0.06 per share

Profitability

Net Income$-18,070,000.00
Net Margins-1,070.82%

Miscellaneous

Employees8
Market Cap$140.92 million
Next Earnings Date8/20/2020 (Estimated)
OptionableNot Optionable
$1.76
+0.05 (+2.92 %)
(As of 08/14/2020 09:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVCO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVCO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avalon Globocare (NASDAQ:AVCO) Frequently Asked Questions

How has Avalon Globocare's stock price been impacted by COVID-19 (Coronavirus)?

Avalon Globocare's stock was trading at $1.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVCO stock has increased by 64.5% and is now trading at $1.76.
View which stocks have been most impacted by COVID-19
.

When is Avalon Globocare's next earnings date?

Avalon Globocare is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020.
View our earnings forecast for Avalon Globocare
.

How were Avalon Globocare's earnings last quarter?

Avalon Globocare Corp (NASDAQ:AVCO) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.03) EPS for the quarter. The company earned $0.41 million during the quarter. Avalon Globocare had a negative net margin of 1,070.82% and a negative return on equity of 299.34%.
View Avalon Globocare's earnings history
.

Has Avalon Globocare been receiving favorable news coverage?

Press coverage about AVCO stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avalon Globocare earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Avalon Globocare
.

Are investors shorting Avalon Globocare?

Avalon Globocare saw a decrease in short interest in May. As of May 15th, there was short interest totaling 683,600 shares, a decrease of 10.2% from the April 30th total of 761,500 shares. Based on an average trading volume of 256,300 shares, the short-interest ratio is currently 2.7 days. Approximately 2.8% of the shares of the stock are sold short.
View Avalon Globocare's Short Interest
.

Who are some of Avalon Globocare's key competitors?

What other stocks do shareholders of Avalon Globocare own?

Who are Avalon Globocare's key executives?

Avalon Globocare's management team includes the following people:
  • Dr. David K. Jin, CEO, Pres & Director (Age 51)
  • Ms. Luisa Ingargiola, Chief Financial Officer (Age 52)
  • Ms. Meng Li, COO, Sec. & Director (Age 41)
  • Dr. Yu Zhou M.D., Ph.D., Co-CEO & Director of GenExsome

What is Avalon Globocare's stock symbol?

Avalon Globocare trades on the NASDAQ under the ticker symbol "AVCO."

How do I buy shares of Avalon Globocare?

Shares of AVCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avalon Globocare's stock price today?

One share of AVCO stock can currently be purchased for approximately $1.76.

How big of a company is Avalon Globocare?

Avalon Globocare has a market capitalization of $140.92 million and generates $1.55 million in revenue each year. Avalon Globocare employs 8 workers across the globe.

What is Avalon Globocare's official website?

The official website for Avalon Globocare is www.avalon-globocare.com.

How can I contact Avalon Globocare?

Avalon Globocare's mailing address is 4400 ROUTE 9 SUITE 3100, FREEHOLD NJ, 07728. The company can be reached via phone at 732-780-4400 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.